Complex medicine for metaphylaxis of calcium oxalate nephrolithiasis.
Authors:   the department of N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation, Prosyannikov M.Yu. ,   Moscow, Russia, Voytko D.A. ,   N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation; Moscow, Russia, Anokhin N.V. ,   the Department of urolithiasis of N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre; Moscow, Russia, Konstantinova O.V. ,   the Department of urolithiasis of N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation; Moscow, Russia, Sivkov A.V. ,   N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation; Moscow, Russia, Apolikhin O.I. ,   N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation; Moscow, Russia, Kaprin A.D. ,   the National Medical Research Centre of Radiology of Ministry of health of Russian Federation, director of P.A. Herzen Institution, Head of Department of Oncology and Radiology named after V.P. Kharchenko of RUDN University; Moscow, Russia
Published: November 2024

Introduction. In the structure of urolithiasis, the predominant number of patients have stones consisting of calcium oxalate. These stones have a dense structure that is not amenable to litholysis and grows quickly. At the moment, there are no medications that can non-invasively relieve patients of this type of stones. In this connection, the main methods of treatment, depending on the size of the stones, are either lithokinetic therapy or surgical treatment. However, stone removal does not eliminate the cause of stone formation, and with this approach, relapse of the disease occurs within 5 years in 30-50% of patients. Today, the search for new approaches and means to reduce the risk of recurrence of calcium oxalate stones does not stop. One of these products is a representative of the Lit-Сontrol® Litura® line from Devicare (Spain) – Litura® Balance. The purpose of this publication is to theoretically substantiate the potential clinical effects of Litura® Balance in the metaphylaxis of calcium oxalate stones. Materials and methods. A literature search and analysis of foreign and domestic literature was carried out using the databases SCOPUS/ScienceDirect, PubMed/MEDLINE, eLibrary, Google Scholar, from 1990 to 2024 using keywords – the active components of Lit-Control® pH Balance – phytate, phytic acid, magnesium and polyphenols, vitamin A, zinc. References in included sources were reviewed to identify additional potentially relevant studies. 167 sources were found, based on relevance, of which 52 articles were selected. Results. The use of Litura® Balance has a scientific basis, and the included substances and their combination potentiate the clinical effect in the metaphylaxis of calcium oxalate stones. However, controlled clinical studies are necessary to assess the prospects for using these complex agents. Conclusions. The results of international experimental and clinical studies allow us to conclude that the complex product Litura® Balance, used to inhibit the processes of calcium oxalate crystallization and antioxidant protection of the urothelium, can be considered as a new promising approach to the metaphylaxis of calcium kidney stones.